Transforming the future use of injectable medicines outside the hospital: Increasing capacity in the NHS

改变未来医院外注射药物的使用：提高 NHS 的能力

• 批准号: EP/X025470/1
• 负责人: Andrew Watts
• 金额: $ 427.92万
• 依托单位: University of Bath
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FX025470%2F1
• 关键词: Transforming; future; use; injectable; medicines

Aseptic compounding is an area where practice has been transformed by the emergence of more complex, personalised medicines. The demands on aseptic dispensing are continually increasing, with clinical teams relying on increasingly complex compounds for treatments given every single day.This Prosperity Partnership aims to create a platform that will transform the future use of injectable medicines in the UK and globally. We envisage, ultimately, a range of reformulated injectable medicines suited to the setting in which they are administered, whether in the community or a hospital, manufactured through an automated process dramatically reducing the demand placed on healthcare resource required to deliver them in whatever setting is appropriate. This potentially requires a wholesale reconfiguration of compounding service in England around a hub and spoke model with high degrees of standardisation and the adaption/adoption of new approaches to automation making more efficient use of resources both in pharmacy/compounding and in the nursing workforce transforming the use of injectable medicines. Underpinning the interlinked delivery of these medicines is a continual drive for extended shelf-lives (stability), simplicity in administration, volume of manufacture, supply chain and cost reduction.Our project focusses on the nexus of these points, considering medicine formulation, manufacture and distribution as a whole system, where elements of the compounding process can occur across different sites, with different scalability and optimisation depending on both use/requirement and shelf-life/complexity of formulation and aseptic manufacturing facility requirements. This incorporates implementing robotics manufacturing and AI into the heavily regulated area of high variation medicines production.

无菌复合是一个因更复杂、个性化药物的出现而改变实践的领域。对无菌配药的需求不断增加，临床团队每天都依赖日益复杂的化合物进行治疗。这一繁荣合作伙伴关系旨在创建一个平台，改变英国和全球注射药物的未来使用。我们设想，最终，一系列重新配制的注射药物适合其给药环境，无论是在社区还是医院，通过自动化过程生产，大大减少在任何适当的环境中提供这些药物所需的医疗资源的需求。这可能需要围绕高度标准化的中心辐射模型对英格兰的配药服务进行大规模重新配置，并采用新的自动化方法，从而更有效地利用药房/配药和护理人员的资源，从而改变注射药物的使用。支撑这些药物相互关联的交付的是对延长保质期（稳定性）、简化管理、制造量、供应链和降低成本的持续推动。我们的项目重点关注这些点的联系，将药物配方、制造和分销视为一个整体系统，其中复合过程的要素可以发生在不同的地点，根据药物的使用/要求和保质期/复杂性，具有不同的可扩展性和优化。 配方和无菌生产设施要求。这将机器人制造和人工智能纳入严格监管的高变异药品生产领域。